Swiss pharma giant Roche Holding AG (RHHBY) posted better-than-expected 2024 results and provided an encouraging outlook for 2025.Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus Estimate of $68 billion. Earnings per American Depositary Receipt of $2.67 also beat the Zacks Consensus Estimate of $2.56.Sales grew 7% year over year at constant exchange rates (CER) to CHF 60.5 billion, driven by strong demand for both drugs and diagnostics.Find the latest EPS estimates and surprises on Zacks ...